Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01839344 · ClinicalTrials.gov registry record · Phase 2
Effects of Quercetin on Blood Sugar and Blood Vessel Function in Type 2 Diabetes.
A Phase 2 study, sponsored by Bastyr University.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT01839344 is a Phase 2 study that has completed, run by Bastyr University. The registered enrollment target is 19 participants.
The verdict
NCT01839344, a Phase 2 study, has completed, sponsored by Bastyr University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to measure the effect of quercetin on glucose tolerance and postprandial endothelial function in comparison to placebo and Acarbose in participants with Type 2 Diabetes. Primary Hypothesis: We hypothesize that administration of quercetin (2g oral) prior to a 100g maltose tolerance test (MTT) will result in a decrease in postprandial blood glucose at 60 minutes compared to placebo. Acarbose (100mg oral), a pharmaceutical alpha-glucosidase inhibitor, will serve as a positive control. Secondary Hypothesis: We hypothesize that administration of quercetin (2g oral) will reduce the Area Under the Glucose Curve (AUC) for the 2 hours following a 100g MTT compared to placebo. AUC is hypothesized to be comparable between quercetin and Acarbose. Tertiary hypothesis: We hypothesize that administration of quercetin (2g oral) prior to a 100g MTT will result in a smaller reduction in flow mediated dilation (FMD) measured as an increase in Reactive Hyperemia Index (RHI) at 90 minutes compared to placebo.
Interventions
- DRUG placebo
- DIETARY_SUPPLEMENT Quercetin
- DRUG Acarbose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2013-05 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01839344
The ClinicalTrials.gov registry entry for NCT01839344 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bastyr University, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01839344 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01839344 about?
NCT01839344 is a clinical study titled "Effects of Quercetin on Blood Sugar and Blood Vessel Function in Type 2 Diabetes.". The purpose of this study is to measure the effect of quercetin on glucose tolerance and postprandial endothelial function in comparison to placebo and Acarbose in participants with Type 2 Diabetes. Primary Hypothesis: We hypothesize that administration of quercetin (2g oral) prior to a 100g maltos...
What is the current status of trial NCT01839344?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2013-05. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01839344?
The interventions under investigation include: placebo (DRUG), Quercetin (DIETARY_SUPPLEMENT), Acarbose (DRUG).
Who is sponsoring clinical trial NCT01839344?
This trial is sponsored by Bastyr University, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.